KalVista Pharmaceuticals to Present New Sebetralstat Data at AAAAI: A Game Changer for HAE Treatment

KalVista Pharmaceuticals (NASDAQ: KALV) is set to present new data on its investigational oral treatment, sebetralstat, at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in February 2025. This presentation comes on the heels of the company's recent announcements regarding the KONFIDENT-KID and KONFIDENT-S studies, which are evaluating the long-term safety and efficacy of sebetralstat in pediatric and adolescent/adult patients with hereditary angioedema (HAE), respectively.

The new data to be presented at AAAAI is expected to provide further insights into the safety and efficacy of sebetralstat as an on-demand treatment for HAE attacks. The presentation will focus on the KONFIDENT-S study, which is an open-label extension trial evaluating the long-term safety of sebetralstat for on-demand treatment of HAE attacks in adolescent and adult patients with type I or type II HAE.

The KONFIDENT-S study is designed to enroll up to 150 patients, with a primary endpoint of assessing the long-term safety of sebetralstat. Secondary endpoints include evaluating the efficacy of sebetralstat in treating HAE attacks, as well as assessing the impact of sebetralstat on quality of life and patient-reported outcomes. The study is expected to be completed in 2026, with topline data anticipated in the second half of 2025.

The presentation of new data on sebetralstat at AAAAI is a significant milestone for KalVista Pharmaceuticals, as it further solidifies the drug's potential as a first-in-class oral on-demand treatment for HAE. The company's ongoing clinical trials and regulatory efforts are aimed at bringing this innovative therapy to patients with HAE, who currently have limited treatment options.



In addition to the KONFIDENT-KID and KONFIDENT-S studies, KalVista Pharmaceuticals is also conducting the KONFIDENT study, which is a Phase 3 clinical trial evaluating the efficacy and safety of sebetralstat for the on-demand treatment of HAE attacks. The company recently announced that it had enrolled more than 50% of the targeted number of patients in the trial, with topline data expected in the second half of 2023.

The presentation of new data on sebetralstat at AAAAI is an important step in the company's ongoing efforts to bring this innovative therapy to patients with HAE. The new data is expected to provide further insights into the safety and efficacy of sebetralstat, as well as its potential to improve the lives of patients with HAE.

In conclusion, KalVista Pharmaceuticals' presentation of new data on sebetralstat at the AAAAI Annual Meeting in February 2025 is a significant milestone in the company's ongoing efforts to bring this innovative therapy to patients with HAE. The new data is expected to provide further insights into the safety and efficacy of sebetralstat, as well as its potential to improve the lives of patients with HAE. As the company continues to advance its clinical trials and regulatory efforts, investors should keep a close eye on KalVista Pharmaceuticals and its potential to revolutionize the treatment of HAE.